Protalix BioTherapeutics – Consensus Indicates Potential 183.2% Upside

Broker Ratings

Protalix BioTherapeutics found using ticker (PLX) now have 2 analysts covering the stock with the consensus suggesting a rating of ‘Buy’. The target price ranges between 15 and 11 with a mean TP of 13. Given that the stocks previous close was at 4.59 this would indicate that there is a potential upside of 183.2%. The day 50 moving average is 3.81 and the 200 day MA is 3.65. The company has a market capitalisation of $153m. Find out more information at: http://www.protalix.com

Protalix BioTherapeutics, a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in Israel, Brazil, rest of Latin America, and internationally. The company offers Elelyso, a plant cell expressed recombinant glucocerebrosidase enzyme for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in phase III clinical trials for the treatment of Fabry diseases; OPRX-106, an orally-delivered protein product candidate for the treatment of inflammatory bowel disease, as well as completed Phase IIa clinical trial for ulcerative colitis patients; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; and PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was founded in 1993 and is headquartered in Karmiel, Israel.

You can now share this on Stocktwits, just click the logo below and add the ticker in the text to be seen.

Share on Stocktwits
You might also enjoy reading  Protalix BioTherapeutics - Consensus Indicates Potential 611.7% Upside

Good news travels fast (but only if you make that happen):

Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on facebook
Facebook
Share on email
Email
Share on reddit
Reddit

AIM All Share Index